Benjamin Cher · · 2 min readSG biotech startup snags $4m seed funding from Elev8, Seeds Capital
Photo credit: Shutterstock
Biotech startup Auristone has secured a US$4 million seed funding round led by venture capital firm Elev8. Seeds Capital, the investment arm of Enterprise Singapore, participated in the funding, along with existing investor Genedant.
“The human epigenome is the next frontier for unlocking precision healthcare,” said Aditya Mathur, managing director at Elev8. “Auristone stands out in this field, with its ability to profile molecules and predict their medical interactions using epigenomics biomarkers.”
The startup is focused on epigenomics, or the science of how genes are expressed. Auristone’s flagship product is a molecular profiling tech called Epi-Call, which helps predict an individual’s likelihood of response to different treatment options for cancer.
The funding will be used to drive more clinical collaborations and market adoption of Epi-Call.
“Seeds Capital looks forward to supporting Auristone as it scales into new markets such as South Korea, Japan and beyond,” said Tan Kaixin, general manager at Seeds Capital. “We are excited to partner with the team to further the adoption of epigenomics in genomic testing and create better, personalized healthcare.”
See also: Series SEA: Who’s investing in the region’s biotech startups?
This story was republished with permission from The Business Times, which made the article available to its paying subscribers. It was moderately edited to reflect Tech in Asia’s editorial guidelines.
Editing by Putra Muskita and Lorenzo Kyle Subido
(And yes, we’re serious about ethics and transparency. More information here.)
Stay updated on the go with our mobile app.
Get latest insights with smoother, more personalized experience through TIA mobile app.
